InsiderTrades.com logo
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>
David Matthew Stark net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Stark Biography and Net Worth

VP of Teva Pharmaceutical Industries
David Stark became Executive Vice President (EVP), Chief Legal Officer in November 2017.

The global Legal Group works hand in hand with Teva’s senior management and its various business units to provide legal advice for the company’s ongoing undertakings, ensuring adherence to applicable laws and regulations in the jurisdictions where Teva conducts its business. Its focus is primarily corporate governance, transactions and intellectual property matters.

Since joining Teva in 2002, David has served in a series of roles with increasing responsibilities in Teva North America and Teva Americas, including as Senior Director, Deputy General Counsel, and Vice President and General Counsel.

Prior to joining Teva, he was an associate attorney in the litigation departments at Willkie Farr & Gallagher LLP, Chadbourne & Parke and Haight, Gardner, Poor & Havens.

David received a J.D. from New York University School of Law and a B.A. in political science from Northeastern University, summa cum laude.

What is David Matthew Stark's net worth?

The estimated net worth of David Matthew Stark is at least $674,231.90 as of March 6th, 2023. Mr. Stark owns 52,449 shares of Teva Pharmaceutical Industries stock worth more than $674,232 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Stark may own. Learn More about David Matthew Stark's net worth.

How do I contact David Matthew Stark?

The corporate mailing address for Mr. Stark and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on David Matthew Stark's contact information.

Has David Matthew Stark been buying or selling shares of Teva Pharmaceutical Industries?

David Matthew Stark has not been actively trading shares of Teva Pharmaceutical Industries during the last quarter. Most recently, David Matthew Stark sold 16,491 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $9.93, for a transaction totalling $163,755.63. Following the completion of the sale, the vice president now directly owns 52,449 shares of the company's stock, valued at $520,818.57. Learn More on David Matthew Stark's trading history.

Who are Teva Pharmaceutical Industries' active insiders?

Teva Pharmaceutical Industries' insider roster includes Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.

Are insiders buying or selling shares of Teva Pharmaceutical Industries?

During the last twelve months, insiders at the sold shares 9 times. They sold a total of 480,586 shares worth more than $5,931,942.06. The most recent insider tranaction occured on March, 5th when EVP Mark Sabag sold 100,000 shares worth more than $1,352,000.00. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.

Information on this page was last updated on 3/5/2024.

David Matthew Stark Insider Trading History at Teva Pharmaceutical Industries

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2023Sell16,491$9.93$163,755.6352,449View SEC Filing Icon  
2/28/2023Sell63,383$9.89$626,857.872,974View SEC Filing Icon  
7/28/2022Sell58,163$9.04$525,793.522,974View SEC Filing Icon  
2/28/2022Sell6,452$8.14$52,519.28View SEC Filing Icon  
2/9/2022Sell6,110$9.06$55,356.60View SEC Filing Icon  
5/11/2021Sell37,884$10.22$387,174.4840,858View SEC Filing Icon  
3/17/2020Sell2,359$7.16$16,890.445,333View SEC Filing Icon  
2/14/2020Sell17,016$12.14$206,574.2416,064View SEC Filing Icon  
2/10/2020Sell12,538$12.24$153,465.1215,512View SEC Filing Icon  
See Full Table

David Matthew Stark Buying and Selling Activity at Teva Pharmaceutical Industries

This chart shows David Matthew Stark's buying and selling at Teva Pharmaceutical Industries by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Read More

Today's Range

Now: $12.86
Low: $12.51
High: $13.01

50 Day Range

MA: $13.48
Low: $12.01
High: $14.44

2 Week Range

Now: $12.86
Low: $7.09
High: $14.47

Volume

10,124,986 shs

Average Volume

10,678,655 shs

Market Capitalization

$14.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05
Tiny Biotech Stock Wins $75 Billion Patent
From Behind the Markets   |   Ad
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Find out more here >>>